Recent Investment Analysts’ Ratings Changes for Viking Therapeutics (VKTX)

Several analysts have recently updated their ratings and price targets for Viking Therapeutics (NASDAQ: VKTX):

• 5/1/2026 – Viking Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $125.00 price target on the stock.
• 4/30/2026 – Viking Therapeutics was given a new $95.00 price target by Morgan Stanley.
• 4/30/2026 – Viking Therapeutics had its price target lowered by Cantor Fitzgerald from $105.00 to $100.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Viking Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/20/2026 – Viking Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/26/2026 – Viking Therapeutics is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 3/23/2026 – Viking Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $102.00 price target on the stock.

Insiders Place Their Bets

In other news, insider Neil William Aubuchon bought 4,475 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $33.50 per share, with a total value of $149,912.50. Following the completion of the acquisition, the insider owned 4,475 shares in the company, valued at $149,912.50. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.30% of the company’s stock.

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non?alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor?beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.